What Is Janssen Doing To Increase Patient Diversity In Trials?

Source: Clinical Leader

Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male.

In this webinar segment, Cassandra Smith, director of diversity & inclusion in clinical trials for Janssen, discusses what Janssen is doing to increase recruitment of minority patients. The company started with a strategy to oversee the diversity effort. That strategy includes taking a close look at trial protocols, barriers to participation, and a careful site selection process. The strategy also involves sharing information about clinical research via educational outreach. Smith also discusses the factors that made the company’s LOTUS trial successful in recruiting women of color.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader